Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Shares Are Crashing Today

By Keith Speights - May 15, 2019 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate.

What happened

Shares of ImmunoGen (IMGN 4.35%) had fallen 31.3% as of 11:08 a.m. EDT on Wednesday. The plunge began after ImmunoGen announced that the U.S. Food and Drug Administration (FDA) wants it to conduct another phase 3 clinical study of experimental ovarian cancer drug mirvetuximab soravtansine before seeking approval for it.

So what

ImmunoGen announced in March that in its late-stage Forward I clinical trial, mirvetuximab soravtansine failed to meet the primary endpoint of progression-free survival in either the entire group of enrolled patients or the prespecified subset of patients with high folate receptor alpha expression. However, the company had hoped to be able to file for FDA approval based on the drug's meeting secondary endpoints in the study.

Scientist wearing a mark with a dropper and test tubes in the foreground

Image source: Getty Images.

That's not a viable path now. The FDA told ImmunoGen that the data on the secondary endpoints of the Forward I study couldn't be used to support a filing for accelerated approval of mirvetuximab. However, the FDA did provide some guidance for designing another study that could lead to approval for the drug.

ImmunoGen is taking the bad news as well as it can. Chief Medical Officer Anna Berkenblit said, "We appreciate the constructive engagement with [the] FDA and look forward to aligning with the agency on the design of a new registration trial in this population." CEO Mark Enyedy added, "Our meeting with [the] FDA enabled us to clarify a regulatory path forward for mirvetuximab and we are evaluating all avenues to bring this promising therapy to ovarian cancer patients."

Now what

ImmunoGen continues to evaluate mirvetuximab in combination with other drugs. The company will also work with the FDA on finalizing the design of another phase 3 study in hopes of eventually winning approval to treat ovarian cancer.

Cash could be an issue down the road, though. ImmunoGen had close to $270 million in cash and cash equivalents at the end of the first quarter. The company is reviewing its operations to identify potential ways to stretch out its cash now that potential FDA approval for its lead pipeline candidate has been pushed further into the future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$3.84 (4.35%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.